Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 57,78 € (+50,51%). La mediana è 55,34 € (+44,15%).
| Acquista |
38 |
| Mantieni |
6 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Boston Scientific draws buys from US politicians as company recovers from cyberattack
Recent filings show Rep. Gilbert Ray Cisneros, Jr. and Rep. Ro Khanna purchased Boston Scientific shares in August. BSX has fallen about 50% year-to-date after a cyberattack disrupted manufacturing and shipments, but production and distribution were reported returning to normal by Sept. 8. Bulls argue lost revenue may be delayed rather than permanent and point to 7.5% Q2 revenue growth and several high-growth franchises, while bears highlight pre-attack slowdowns in key product lines, competitive pressures, integration debt from the Penumbra acquisition, and potential customer losses. The stock trades at about 13.1x forward non-GAAP earnings, roughly 30% below the healthcare-sector median. » Altro su finance.yahoo.com
Boston Scientific cuts 2026 guidance after cyberattack disrupts manufacturing and shipping
Boston Scientific disclosed that an August 25 cyberattack disrupted manufacturing and order fulfilment, prompting a warning that it is unlikely to meet prior third-quarter and full-year 2026 net sales and adjusted EPS guidance. Operations and distribution have resumed, but lost shipments will weigh on near-term results and could risk market share recovery for its Farapulse PFA system amid competition. The incident exposes an operational vulnerability and made the financial impact difficult to quantify, increasing uncertainty ahead of third-quarter results. Institutional positioning has eased modestly and the company remains a potential recovery candidate, but visibility and valuation risk are elevated until order rates and EP market share stabilize. » Altro su finance.yahoo.com
Cyberattack weighs on Boston Scientific outlook
Boston Scientific says an eight-day cyberattack disrupted global operations and will likely cause it to miss Q3 and full-year 2026 guidance, although IT, sales and manufacturing systems have now been restored. Demand for WATCHMAN remains weak in the near term; U.S. procedures are expected to decline by the mid- to high-single digits in H2 2026, and market share in pulse field ablation (FARAPULSE) has fallen to about 50%. Management expects only minimal EPS growth in 2027 but anticipates a return to more typical growth in 2028, cites several product launches as drivers, and confirms the planned acquisition of Penumbra is on track to close by the end of 2026. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | |
|---|---|---|
| Ricavi | 4,77 Mld | 11,05% |
| Utile lordo | 3,37 Mld | 16,06% |
| Utile netto | 794,72 Mln | 18,12% |
| EBITDA | 1,22 Mld | 4,94% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 55,67 Mld € |
Numero di azioni | 1,49 Mld |
Massimo/minimo a 52 settimane | 92,07 € - 36,77 € |
| Dividendi | No |
Beta | 0,57 |
Rapporto P/E | 17,33 |
Rapporto PEG | 0,38 |
Rapporto P/B | 2,55 |
Rapporto P/S | 3,04 |
Profilo aziendale
Die Boston Scientific Corporation entwickelt, produziert und vertreibt weltweit medizinische Geräte für den Einsatz in verschiedenen interventionellen medizinischen Fachgebieten. Das Unternehmen ist in drei Segmenten tätig: MedSurg, Rhythm and Neuro, und Cardiovascular. Das Unternehmen bietet Geräte zur Diagnose und Behandlung von Magen-Darm- und Lungenerkrankungen, Geräte zur Behandlung verschiedener urologischer und pelviner Erkrankungen, implantierbare Kardioverter und implantierbare Herz-Resynchronisations-Therapie-Defibrillatoren, Herzschrittmacher und implantierbare Herz-Resynchronisations-Therapie-Schrittmacher sowie Remote-Patienten-Management-Systeme. Darüber hinaus bietet das Unternehmen Medizintechnologien zur Diagnose und Behandlung von Herzrhythmusstörungen an, darunter 3D-Kardio-Mapping- und Navigationslösungen, Ablationskatheter, Diagnosekatheter, Mapping-Katheter, intrakardiale Ultraschallkatheter, Einführschleusen und anderes Zubehör, Rückenmarkstimulatorsysteme für die Behandlung chronischer Schmerzen, indirekte Dekompressionssysteme und Systeme zur Tiefenhirnstimulation. Darüber hinaus bietet das Unternehmen Produkte für die interventionelle Kardiologie an, darunter medikamentenfreisetzende Koronarstentsysteme zur Behandlung der Koronararterienerkrankung, Produkte für die perkutane Koronarintervention zur Behandlung von Atherosklerose, Katheter für die intravaskuläre Ultraschallbildgebung, Geräte für die fraktionierte Flussreserve und Systeme für den Einsatz in Koronararterien und Herzkammern sowie in verschiedenen peripheren Gefäßen und strukturelle Herztherapien. Darüber hinaus bietet das Unternehmen Stents, Ballonkatheter, Drähte und Atherektomiesysteme zur Behandlung von Arterienerkrankungen, Thrombektomie- und akustische Impulsthrombolysesysteme, Drähte und Stents zur Behandlung von Venenerkrankungen sowie periphere Embolisationsgeräte, radioaktive Mikrosphären, Ablationssysteme, Kryotherapie-Ablationssysteme und Mikro- und Drainagekatheter zur Behandlung von Krebs. Das Unternehmen wurde 1979 gegründet und hat seinen Hauptsitz in Marlborough, Massachusetts.
| Nome | Boston Scientific |
| CEO | Michael F. Mahoney |
| Sede centrale | Marlborough,
ma Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Attrezzature e forniture sanitarie |
| Quotazione in borsa | 19/11/2019 |
| Dipendenti | 59.000 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | BSX |
London Stock Exchange | 0HOY.L |
XETRA | BSX.F |
Frankfurt | BSX.F |
Düsseldorf | BSX.DU |
Milan | 1BSX.MI |
London | 0HOY.L |
SIX | BSX.SW |
München | BSX.MU |
Wien | BSXC.VI |
